Abstract
We designed a novel recombinant fusion protein r-NAP5-hirudin 12-residue-RGD with bi-functional inhibitory activities against platelet aggregation and thrombin. Our strategy may supply a potential multi-functional drug for the prevention and management of thrombosis.
Keywords: Thrombosis, Hirudin 12-residue, Thrombin, NAP5, Platelet aggregation, Recombinant fusion protein
Letters in Drug Design & Discovery
Title: A Novel Recombinant Fusion Protein Exhibited Inhibitory Activities on Platelet Aggregation and Thrombin
Volume: 7 Issue: 3
Author(s): Zongli Hu, Zhiping Zhao, Yan Liang, Yong Li and Guoping Chen
Affiliation:
Keywords: Thrombosis, Hirudin 12-residue, Thrombin, NAP5, Platelet aggregation, Recombinant fusion protein
Abstract: We designed a novel recombinant fusion protein r-NAP5-hirudin 12-residue-RGD with bi-functional inhibitory activities against platelet aggregation and thrombin. Our strategy may supply a potential multi-functional drug for the prevention and management of thrombosis.
Export Options
About this article
Cite this article as:
Hu Zongli, Zhao Zhiping, Liang Yan, Li Yong and Chen Guoping, A Novel Recombinant Fusion Protein Exhibited Inhibitory Activities on Platelet Aggregation and Thrombin, Letters in Drug Design & Discovery 2010; 7 (3) . https://dx.doi.org/10.2174/157018010790596605
DOI https://dx.doi.org/10.2174/157018010790596605 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cytostatic Properties of Some Angiotensin I Converting Enzyme Inhibitors and of Angiotensin II Type I Receptor Antagonists
Current Pharmaceutical Design Gas Bioengineering Using Hemoglobin-Vesicles For Versatile Clinical Applications
Current Pharmaceutical Design Therapeutic Modulation of Coagulation and Fibrinolysis in Acute Lung Injury and the Acute Respiratory Distress Syndrome
Current Pharmaceutical Biotechnology Nitric Oxide and L-Arginine Deficiency in Cystic Fibrosis
Current Pharmaceutical Design Targeting the Human Thioredoxin System by Diverse Strategies to Treat Cancer and Other Pathologies
Recent Patents on DNA & Gene Sequences Primary Sjögren’s Syndrome and Cardiovascular Disease
Current Vascular Pharmacology Unusual Clinical Manifestations of the Antiphospholipid Syndrome
Current Rheumatology Reviews Toxicity of Carbon Nanotubes
Current Drug Metabolism Myocardial Infarction Following Atherosclerosis in Murine Models
Current Drug Targets Therapeutic Potential of Janus Kinase 3 (JAK3) Inhibitors
Current Pharmaceutical Design Role of Physician Gender in the Quality of Care of Cardiometabolic Diseases
Current Pharmaceutical Design The Protective Effects of Natural Products on Blood-Brain Barrier Breakdown
Current Medicinal Chemistry General or Local Anesthesia for TAVI? A Systematic Review of the Literature and Meta-Analysis
Current Pharmaceutical Design The Acid Sphingomyelinase/Ceramide Pathway: Biomedical Significance and Mechanisms of Regulation
Current Molecular Medicine Protein Regulators of Eicosanoid Synthesis: Role in Inflammation
Current Protein & Peptide Science Cartilage Oligomeric Matrix Protein: Matricellular and Matricrine Signaling in Cardiovascular Homeostasis and Disease
Current Vascular Pharmacology Antiplatelet Treatment in Peripheral Arterial Disease: The Role of Novel Antiplatelet Agents
Current Pharmaceutical Design Patent Ductus Arteriosus in Extreme Prematurity: Role of Echocar-diography and Other Imaging Techniques
Current Pediatric Reviews Current and Emerging Therapies in Neuroendocrine Tumors: Impact of Genetic Targets on Clinical Outcomes
Clinical Cancer Drugs ROCK Inhibitors as Emerging Therapeutic Candidates for Sarcomas
Current Cancer Drug Targets